Shenzhen Neptunus Bioengineering Co., Ltd. Class A

As of June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A carries a market capitalization of 3.39B, placing it among publicly traded companies globally. Its enterprise value stands at 12.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A has 2.63B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.15, and the price-to-book ratio stands at 3.32.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.00B versus a market cap of 3.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 549.51, indicating elevated leverage, while an interest coverage ratio of -1.34 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A posted a negative return on equity (ROE) of -55.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.00, reflecting losses generated across the asset base. The company generates approximately 3.29M in revenue per employee across its workforce of 7,116.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.74 indicates how many times Shenzhen Neptunus Bioengineering Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A recorded 11.37M in income tax expense. The company reported a pretax loss of -799.95M and -784.75M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A's stock has declined approximately 48.45% over the past 52 weeks. The 50-day moving average sits at 1.53, while the 200-day moving average is 2.46.

Over the twelve months ended June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A generated 23.39B in revenue and converted that into -784.75M in net income, yielding earnings per share of -0.31. EBITDA reached -807.95M, while operating income came in at 367.80M.

As of June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A holds 2.41B in cash and equivalents against 10.19B in total debt, resulting in a net debt position of 7.70B. Total book value stands at 1.02B, with working capital of -340.08M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A posted a gross margin of 9.31, reflecting its pricing power and cost economics. The operating margin of 1.57 and net profit margin of -3.36 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A paid dividends of 0.19 per share. The dividend payout ratio of -59.94 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -3.89, meaning Shenzhen Neptunus Bioengineering Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shenzhen Neptunus Bioengineering Co., Ltd. Class A's most recent stock split took place on May 27, 2016 with a 2:5 split ratio.

As of June 30, 2026, Shenzhen Neptunus Bioengineering Co., Ltd. Class A has an Altman Z-Score of 0.92, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.